{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-22-000118","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2022-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.958300+00:00","generated_at":"2026-06-23T07:01:16.702384+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immunovant announces next-generation anti-FcRn IMVT-1402 with promising preclinical data","bullets":["IMVT-1402 showed deep IgG lowering with minimal impact on albumin and LDL in animal studies.","Plan to submit IND and initiate Phase 1 study in early 2023 with initial data expected in mid-2023.","Cash runway guidance into calendar year 2025 remains unchanged, including Phase 1 costs for IMVT-1402.","Composition of matter patent protection expected for IMVT-1402 through at least 2042.","Batoclimab programs in Myasthenia Gravis, Thyroid Eye Disease, CIDP and Graves' Disease continue at full speed."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-22-000118","json":"https://secwatch.observer/filing/0001764013-22-000118.json","markdown":"https://secwatch.observer/filing/0001764013-22-000118.md","text":"https://secwatch.observer/filing/0001764013-22-000118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000118/0001764013-22-000118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000118/imvt-20220928.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:01:16.702384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}